Accretion Pharmaceuticals (NSE:ACCPL) Ending Cash Position: ₹38.6 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ACCPL Accretion Pharmaceuticals Ltd NSE:ACCPL
22 GF Score
Price ₹202.30
! 6 Warning Signs
View Full Analysis

What is Accretion Pharmaceuticals Ending Cash Position?

Accretion Pharmaceuticals NSE:ACCPL -2.74% 22 Ending Cash Position is ₹38.6 Mil as of Mar. 2026. GuruFocus rates NSE:ACCPL with a GF Score™ of 22/100. The stock has 6 warning signs investors should review.

Accretion Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 was ₹38.6 Mil.

Accretion Pharmaceuticals's quarterly Ending Cash Position increased from Mar. 2025 (₹0.0 Mil) to Sep. 2025 (₹1.6 Mil) and increased from Sep. 2025 (₹1.6 Mil) to Mar. 2026 (₹38.6 Mil).

Accretion Pharmaceuticals's annual Ending Cash Position declined from Mar. 2024 (₹0.9 Mil) to Mar. 2025 (₹0.5 Mil) but then increased from Mar. 2025 (₹0.5 Mil) to Mar. 2026 (₹40.2 Mil).

Accretion Pharmaceuticals Ending Cash Position Related Terms

Accretion Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Accretion Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accretion Pharmaceuticals Ending Cash Position Chart

Accretion Pharmaceuticals Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
3.75 0.36 0.92 0.51 40.21

Accretion Pharmaceuticals Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Ending Cash Position Get a 7-Day Free Trial 0.00 0.00 0.00 1.56 38.65
NSE:ACCPL
22GF Score
Accretion Pharmaceuticals Ltd NSE:ACCPL
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accretion Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Accretion Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.50699999999999+39.699
=40.2

Accretion Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=-0.00099999999999767+38.649
=38.6

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ₹38.6 Mil mean?
Accretion Pharmaceuticals (NSE:ACCPL) has a Ending Cash Position of ₹38.6 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Accretion Pharmaceuticals and its competitors.
Is Accretion Pharmaceuticals' Ending Cash Position too high?
Accretion Pharmaceuticals' current Ending Cash Position is ₹38.6 Mil. Overall, Accretion Pharmaceuticals has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' Ending Cash Position compare to LLY and JNJ?
Accretion Pharmaceuticals' Ending Cash Position of ₹38.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Accretion Pharmaceuticals and its competitors. Accretion Pharmaceuticals's current Ending Cash Position is ₹38.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current Ending Cash Position of ₹38.6 Mil. The current Ending Cash Position is ₹38.6 Mil. Accretion Pharmaceuticals' overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current Ending Cash Position is ₹38.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accretion Pharmaceuticals Business Description

Address 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna-Chacharwadi, Ta - Sanand District, Ahmedabad, GJ, IND, 382213
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
22GF Score

Get the complete analysis for NSE:ACCPL

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹202.30
Price